AZN supply chain intelligence for AstraZeneca PLC: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CGEN | Compugen Ltd. | 92% | Reciprocal relationship from CGEN graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CGEN graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CGEN gra… |
| HBIO | Harvard Bioscience, Inc. | 92% | Reciprocal relationship from HBIO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from HBIO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from HBIO gra… |
| IONS | Ionis Pharmaceuticals, Inc. | 92% | Reciprocal relationship from IONS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IONS graph: We determined that we had a vendor-customer relationship within the scope of … |
| IRWD | Ironwood Pharmaceuticals, Inc. | 92% | Reciprocal relationship from IRWD graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IRWD gra… |
| KYNB | Kyntra Bio, Inc. | 85% | Reciprocal relationship from KYNB graph: In July 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AstraZeneca for roxadustat for the trea… |
| ALLR | Allarity Therapeutics, Inc. | 72% | Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the… |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS gra… |
| CRNX | Crinetics Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CRNX graph: products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement … |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904… |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with… |
| KNSA | Kiniksa Pharmaceuticals International, plc | 72% | Reciprocal relationship from KNSA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from KNSA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from KNSA gra… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: Reciprocal relationship from AZN graph: Reciprocal relationship from MGNX graph: n exclusive option to license worldwide rights to the research program, upon … |
| MRNA | Moderna, Inc. | 72% | Reciprocal relationship from MRNA graph: sease in birds known as avian influenza and poses a risk of spillover into the human population. The agreement also includes additional options to prepare for… |
| NUVB | Nuvation Bio Inc. | 72% | Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a lon… |
| PLRX | Pliant Therapeutics, Inc. | 72% | Reciprocal relationship from PLRX graph: Reciprocal relationship from AZN graph: Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commercializ… |
| PPCB | Propanc Biopharma, Inc. | 72% | Reciprocal relationship from PPCB graph: Reciprocal relationship from AZN graph: Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions … |
| PYXS | Pyxis Oncology, Inc. | 72% | Reciprocal relationship from PYXS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from PYXS gra… |
| RCUS | Arcus Biosciences, Inc. | 72% | Reciprocal relationship from RCUS graph: nd clinical testing. If any of our optioned investigational products obtain marketing approval, we expect to continue to use third-party manufacturers along w… |
| SLN | Silence Therapeutics plc | 72% | Reciprocal relationship from SLN graph: the Group’s operating leases at December 31, 2024: Fiscal year Operating Leases 2025 117 2026 - 2027 - 2028 - 2029 - Thereafter - Total expected lease payments… |
| ZBIO | Zenas BioPharma, Inc. | 72% | Reciprocal relationship from ZBIO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ZBIO gra… |
| MREO | Mereo BioPharma Group plc | 70% | Reciprocal relationship from MREO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from MREO graph: under various agreements with Novartis and AstraZeneca, we have agreed to mak… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | 92% | Reciprocal relationship from IDYA graph: AstraZeneca will supply Imfinzi ® . |
| CLLS | Cellectis S.A. | 90% | Reciprocal relationship from CLLS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CLLS gra… |
| FBIO | Fortress Biotech, Inc. | 90% | Reciprocal relationship from FBIO graph: four subsidiaries have consummated strategic partnerships with industry leaders, including AstraZeneca plc as successor-in-interest to Alexion Pharmaceuticals, Inc. |
| IPHA | Innate Pharma S.A. | 90% | Reciprocal relationship from IPHA graph: The Company has significant collaborations with AstraZeneca for the development of monalizumab and IPH5201. |
| SLN | Silence Therapeutics plc | 90% | Reciprocal relationship from SLN graph: Under this agreement, AstraZeneca made an upfront cash payment to us of $20.0 million in May 2020. |
| ALLR | Allarity Therapeutics, Inc. | 72% | Reciprocal relationship from ALLR graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment… |
| CHRS | Coherus Oncology, Inc. | 72% | Reciprocal relationship from CHRS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors)… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our work… |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: ty contract manufacturers for our CMC and manufacturing needs. These third parties must comply with applicable regulatory requirements, including the FDA’s cG… |
| GLSI | Greenwich LifeSciences, Inc. | 72% | Reciprocal relationship from GLSI graph: duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may o… |
| KYNB | Kyntra Bio, Inc. | 72% | Reciprocal relationship from KYNB graph: straZeneca for the development and commercialization of roxadustat. For the years ended December 31, 2024 and 2023, our revenue for continuing operations was … |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: t and future product candidates. Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we o… |
| MTVA | MetaVia Inc. | 72% | Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered under such registration statements will be available for sale in the open market. In the future, we may also issue our sec… |
| NUVB | Nuvation Bio Inc. | 72% | Reciprocal relationship from NUVB graph: t of our investigational products. We currently have a single source for taletrectinib API and drug product, and we obtain taletrectinib API pursuant to a lon… |
| PLRX | Pliant Therapeutics, Inc. | 72% | Reciprocal relationship from PLRX graph: approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. In addition, there are risks assoc… |
| PPCB | Propanc Biopharma, Inc. | 72% | Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, … |
| PYXS | Pyxis Oncology, Inc. | 72% | Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitab… |
| UPB | Upstream Bio, Inc. | 72% | Reciprocal relationship from UPB graph: ise such that they may be more successful than us in obtaining regulatory approval and achieving widespread market acceptance. • We expect to expand our organi… |
| VXRT | Vaxart, Inc. | 72% | Reciprocal relationship from VXRT graph: Reciprocal relationship from AZN graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from AZN graph: Reciprocal relationship from VXRT gra… |
| ZBIO | Zenas BioPharma, Inc. | 72% | Reciprocal relationship from ZBIO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug subs… |
| F-44-THE-GROUP | F-44-THE-GROUP | 62% | receivables and trade payables, which arise directly from its operations. The principal financial risks to which the Group is exposed are those of liquidity, interest rate, foreign currency and credi… |
| F-9-THE-GROUP | F-9-THE-GROUP | 62% | is allocated between the grant and supply elements. The standalone selling price for the supply of products is determined by reference to observed prices with other customers. The amount allocated as… |
| FUJIFILM-KYOWA-KIRIN-BIOLOGICS-CO-LTD | FUJIFILM-KYOWA-KIRIN-BIOLOGICS-CO-LTD | 62% | enture agreement with Chinese Future Industry Investment Fund (FIIF), to discover, develop and commercialise potential new medicines to help address unmet medical needs globally, and to bring innovat… |
| IMPERIAL-CHEMICAL-INDUSTRIES-PLC | IMPERIAL-CHEMICAL-INDUSTRIES-PLC | 62% | wever, there are various external risk factors that could compromise our ability to execute our pricing strategies as planned. The market access environment is highly complex and subject to dynamic e… |
| LEASES-THE-GROUP | LEASES-THE-GROUP | 62% | is allocated between the grant and supply elements. The standalone selling price for the supply of products is determined by reference to observed prices with other customers. The amount allocated as… |
| POST-ALEXION-ACQUISITION-GROUP | POST-ALEXION-ACQUISITION-GROUP | 62% | t of F-14 these relate to the Medicaid and state programmes with an adjustment in respect of prior year net US Product Sales in 2024 of 0.1 % (2023: 0.3 %; 2022: 0.5 %) and Managed Care and Medicare … |
| SYNGENTA-AG | SYNGENTA-AG | 62% | wever, there are various external risk factors that could compromise our ability to execute our pricing strategies as planned. The market access environment is highly complex and subject to dynamic e… |
| UK-CENTUS-BIOTHERAPEUTICS-LIMITED | UK-CENTUS-BIOTHERAPEUTICS-LIMITED | 62% | enture agreement with Chinese Future Industry Investment Fund (FIIF), to discover, develop and commercialise potential new medicines to help address unmet medical needs globally, and to bring innovat… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| AZN-DEBT | Debt stack $34.0B | 90% | Market cache reports total debt of $34.0B. |
| Acquired Entity | Name | Confidence | Evidence |
|---|---|---|---|
| AZN-ACQ-0001654954-26-001966 | Pascal Soriot acquired 101,495 ordinary shares under the AstraZeneca Performance Share Plan. | 85% | Pascal Soriot acquired 101,495 ordinary shares under the AstraZeneca Performance Share Plan. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| AZN-OWNER-PRIMECAP-MANAGEMENT-COMPANY | Primecap Management Company | 95% | 13F/ownership overlay lists Primecap Management Company; shares held 39,857,971; ownership 1.52%; value $7.5B; as of 2025-09-30. |
| AZN-OWNER-PACER-ADVISORS-INC | Pacer Advisors, Inc. | 95% | 13F/ownership overlay lists Pacer Advisors, Inc.; shares held 15,863; value $3.0M; as of 2025-09-30. |
| AZN-OWNER-PARADIGM-ASSET-MANAGEMENT-COMPANY-LLC | Paradigm Asset Management Company, LLC | 95% | 13F/ownership overlay lists Paradigm Asset Management Company, LLC; shares held 13,100; value $2.5M; as of 2025-09-30. |
| AZN-OWNER-FISHER-ASSET-MANAGEMENT-LLC | Fisher Asset Management, LLC | 95% | 13F/ownership overlay lists Fisher Asset Management, LLC; shares held 21,162,724; ownership 0.81%; value $4.0B; as of 2025-09-30. |
| AZN-OWNER-FRANKLIN-RESOURCES-INC | Franklin Resources, Inc. | 95% | 13F/ownership overlay lists Franklin Resources, Inc.; shares held 19,714,165; ownership 0.75%; value $3.7B; as of 2025-09-30. |
| AZN-OWNER-FNY-INVESTMENT-ADVISERS-LLC | FNY Investment Advisers, LLC | 95% | 13F/ownership overlay lists FNY Investment Advisers, LLC; shares held 200; value $37,979; as of 2025-12-31. |
| AZN-OWNER-SARANAC-PARTNERS-LTD | Saranac Partners Ltd | 95% | 13F/ownership overlay lists Saranac Partners Ltd; shares held 5,817; value $1.1M; as of 2025-09-30. |
| AZN-OWNER-FMR-LLC | FMR, LLC | 95% | 13F/ownership overlay lists FMR, LLC; shares held 21,686,320; ownership 0.83%; value $4.1B; as of 2025-09-30. |
| AZN-OWNER-OLD-MISSION-CAPITAL-LLC | Old Mission Capital, LLC | 95% | 13F/ownership overlay lists Old Mission Capital, LLC; shares held 59,639; value $11.3M; as of 2025-09-30. |
| AZN-OWNER-BANK-OF-AMERICA-CORPORATION | Bank of America Corporation | 95% | 13F/ownership overlay lists Bank of America Corporation; shares held 32,633,139; ownership 1.24%; value $6.1B; as of 2025-09-30. |
| AZN-OWNER-PRICE-T-ROWE-ASSOCIATES-INC | Price (T.Rowe) Associates Inc | 95% | 13F/ownership overlay lists Price (T.Rowe) Associates Inc; shares held 49,124,476; ownership 1.87%; value $9.3B; as of 2025-09-30. |
| AZN-OWNER-WELLINGTON-MANAGEMENT-GROUP-LLP | Wellington Management Group, LLP | 95% | 13F/ownership overlay lists Wellington Management Group, LLP; shares held 32,299,561; ownership 1.23%; value $6.1B; as of 2025-09-30. |
| AZN-OWNER-CAPITAL-INTERNATIONAL-INVESTORS | Capital International Investors | 95% | 13F/ownership overlay lists Capital International Investors; shares held 25,052,520; ownership 0.95%; value $4.7B; as of 2025-09-30. |
| AZN-OWNER-GOLDMAN-SACHS-GROUP-INC | Goldman Sachs Group Inc | 95% | 13F/ownership overlay lists Goldman Sachs Group Inc; shares held 13,671,749; ownership 0.52%; value $2.6B; as of 2025-09-30. |
| AZN-OWNER-SANDERS-CAPITAL-LLC | Sanders Capital, LLC | 95% | 13F/ownership overlay lists Sanders Capital, LLC; shares held 14,058,682; ownership 0.54%; value $2.6B; as of 2025-09-30. |
| AZN-OWNER-BARCLAYS-PLC | BARCLAYS PLC | 90% | 13F overlay lists BARCLAYS PLC as top holder; 1 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | ['customer', 'supplier'] |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| IHG | InterContinental Hotels Group PLC | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BSX | Boston Scientific Corporation | 100.00 | 2 | |
| DFTX | Definium Therapeutics, Inc. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| DNTH | Dianthus Therapeutics, Inc. | 100.00 | 2 |